Clinical Trials Logo

Eye Infections clinical trials

View clinical trials related to Eye Infections.

Filter by:

NCT ID: NCT00996736 Completed - Corneal Ulcer Clinical Trials

Mycotic Ulcer Treatment Trial I

MUTT I
Start date: April 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if natamycin or voriconazole results in better visual outcomes in fungal corneal ulcers, especially visual acuity.

NCT ID: NCT00575380 Completed - Clinical trials for Bacterial Infections

Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery

Start date: December 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the drug concentrations in the conjunctiva and aqueous humor of AzaSiteā„¢ compared to Vigamox® in subjects undergoing routine cataract surgery

NCT ID: NCT00575367 Completed - Clinical trials for Bacterial Infections

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Start date: March 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the drug concentrations of AzaSite compared to Vigamox in tears of healthy volunteers

NCT ID: NCT00564447 Completed - Clinical trials for Bacterial Infections

Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

Start date: December 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the drug concentrations of AzaSiteā„¢ compared to Vigamox at various time points in conjunctiva tissue of healthy volunteers

NCT ID: NCT00357539 Completed - Clinical trials for Eye Infections, Bacterial

Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers

Start date: February 2002
Phase: Phase 1
Study type: Interventional

To compare the ocular tolerance, safety and ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225.

NCT ID: NCT00357383 Completed - Clinical trials for Eye Infections, Bacterial

Study of the Ocular Safety After Repeated Instillations of T1225 1% or 1.5% Eye Drops in Healthy Volunteers

Start date: October 2002
Phase: Phase 1
Study type: Interventional

To evaluate the ocular tolerance of T1225 1% and 1.5% eye drops versus vehicle after one instillation twice-daily (morning and evening), in one eye, during 3 days (from Day 0 to Day 2). To assess azithromycin tear, conjunctiva and plasmatic concentrations, after a 3-day treatment period

NCT ID: NCT00357292 Completed - Clinical trials for Eye Infections, Bacterial

Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

Start date: March 2002
Phase: Phase 1
Study type: Interventional

To compare the ocular tolerance, the safety and the ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225 after one drop instillation

NCT ID: NCT00356850 Completed - Clinical trials for Eye Infections, Bacterial

Ocular Pharmacokinetics After a Single Drop Instillation of T1225 0.5, 1, 1.5% in 91 Healthy Volunteers

Start date: May 2002
Phase: Phase 1
Study type: Interventional

To evaluate azithromycin tear concentrations after instillation of one drop of one of the three T1225 concentrations (0.5%, 1% and 1.5%) and to evaluate the ocular safety.

NCT ID: NCT00356772 Completed - Clinical trials for Eye Infections, Bacterial

Azithromycin Level in Tears and in Conjunctiva in 36 Healthy Volunteers

Start date: February 2003
Phase: Phase 1
Study type: Interventional

To evaluate azithromycin ocular conjunctiva concentrations 7 and 14 days after treatment initiation. To assess ocular and systemic tolerance/safety and azithromycin tear concentrations on Day 7

NCT ID: NCT00324168 Completed - Corneal Ulcer Clinical Trials

Steroids for Corneal Ulcers Trial

SCUT
Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether adding topical steroids improves the outcomes of bacterial corneal ulcers, especially visual acuity.